Click to Translate to English Click to Translate to French  Click to Translate to Spanish  Click to Translate to German  Click to Translate to Italian  Click to Translate to Japanese  Click to Translate to Chinese Simplified  Click to Translate to Korean  Click to Translate to Arabic  Click to Translate to Russian  Click to Translate to Portuguese  Click to Translate to Myanmar (Burmese)

PANDEMIC ALERT LEVEL
123456
Forum Home Forum Home > Main Forums > Latest News
  New Posts New Posts RSS Feed - New antiviral Monulpariver in trials
  FAQ FAQ  Forum Search   Events   Register Register  Login Login

Online Discussion: Tracking new emerging diseases and the next pandemic since 2005; Coronavirus COVID-19 Pandemic Discussion Forum.

New antiviral Monulpariver in trials

 Post Reply Post Reply
Author
Message
Pixie View Drop Down
Admin Group
Admin Group
Avatar

Joined: June 05 2006
Location: United States
Status: Offline
Points: 17313
Post Options Post Options   Thanks (1) Thanks(1)   Quote Pixie Quote  Post ReplyReply Direct Link To This Post Topic: New antiviral Monulpariver in trials
    Posted: December 12 2020 at 9:02am


  https://www.ctpost.com/business/article/Monulparivir-the-drug-that-completely-stops-15779895.php


Monulparivir: The Drug That 'Completely' Stops the Spread of Coronavirus In 24 Hours

Testing on ferrets seem promising.


This antiviral drug could prevent virus carriers from developing severe symptoms and transmitting the disease, as well as containing local outbreaks in a single day, according to studies.


The COVID-19 vaccine may spell the end of the pandemic, but while mass vaccination is not available it is vital to stop community transmission. The new antiviral drug MK-4482 / EIDD-2801 or Molnupiravir, has managed to suppress "completely" the transmission of the coronavirus in just 24 hours , according to studies by the Institute of Biomedical Sciences of Georgia State University.

"This is the first demonstration of an orally available drug that quickly blocks the transmission of SARS-CoV-2 , so it could be a game changer," the researchers explained in the work published in the journal Nature Microbiology.


The antiviral drug was developed at Emory University in Atlanta by the drug innovation company Drug Innovation Ventures at Emory (DRIVE), which was licensed by Ridgeback Biotherapeutics, which partnered with Merck & Co. Molnupiravir was originally designed to treat the flu and prevent the virus from making copies of itself, creating errors during viral RNA replication.


The experts detail that tests were carried out on ferrets and it was observed that they presented a reduction in the amount of viral particles. Then those ferrets were put with others that had not been treated. None of the ferrets in the second group became infected with COVID-19.

"We believe that ferrets are a relevant transmission model because they easily spread SARS-CoV-2, but for the most part they do not develop a serious disease, which is very similar to the spread of SARS-CoV-2 in young adults," he said. Dr. Robert Cox, a postdoctoral fellow in the Plemper group and co-lead author of the study.


“We observed early on that MK-4482 / EIDD-2801 has broad spectrum activity against respiratory RNA viruses and that oral treatment of infected animals with the drug reduces the amount of viral particles spread by several orders of magnitude, drastically reducing transmission. These properties made MK-4482 / EIDD / 2801 a powerful candidate for the pharmacological control of Covid-19 ”, the report adds.


If this ferret-based data is translated into humans, Covid-19 patients treated with the drug could become non-infectious within 24 hours of starting treatment.

The drug can be taken orally, and treatment can be started early for a triple potential benefit: inhibiting patients' progress to severe disease, shortening the infectious phase to alleviate the emotional and socioeconomic cost of prolonged patient isolation, and containing quickly local outbreaks.

Molnupiravir is currently in advanced phase II / III clinical trials. It is being tested in three different doses every 12 hours for five days in patients with SARS-CoV-2.


https://www.nature.com/articles/s41564-020-00835-2?utm_medium=affiliate&utm_source=commission_junction&utm_campaign=3_nsn6445_deeplink_PID100038822&utm_content=deeplink

Back to Top
Technophobe View Drop Down
Assistant Admin
Assistant Admin
Avatar

Joined: January 16 2014
Location: Scotland
Status: Offline
Points: 83700
Post Options Post Options   Thanks (0) Thanks(0)   Quote Technophobe Quote  Post ReplyReply Direct Link To This Post Posted: December 12 2020 at 10:55am

Early days, but good news nonetheless.

ERCD
Back to Top
EdwinSm, View Drop Down
Adviser Group
Adviser Group


Joined: April 03 2013
Status: Offline
Points: 19395
Post Options Post Options   Thanks (1) Thanks(1)   Quote EdwinSm, Quote  Post ReplyReply Direct Link To This Post Posted: December 12 2020 at 10:46pm

If they have been able to advance to stage II/III trials before releasing data on animal testing, then maybe they are more advanced than the release first suggests.   I also notice this is based on work they had been doing for flu so is not a totally new approach, which is also good news.

Back to Top
 Post Reply Post Reply
  Share Topic   

Forum Jump Forum Permissions View Drop Down